probucol has been researched along with Hyperlipoproteinemias in 25 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Hyperlipoproteinemias: Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 7.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 7.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Thirty five patients with cardiovascular diseases and hypercholesterolemia were treated with probucol and a low-fat diet for 12 to 50 months." | 7.66 | [Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)]. ( Renais, J; Scebat, L, 1980) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 3.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 3.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Thirty five patients with cardiovascular diseases and hypercholesterolemia were treated with probucol and a low-fat diet for 12 to 50 months." | 3.66 | [Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)]. ( Renais, J; Scebat, L, 1980) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Probucol is a drug with hypolipidemic effect from the group of diphenols." | 1.27 | [Clinical research on the hypolipidemic action of a probucol preparation]. ( Balabanski, L; Goranov, I; Kerekovska, M; Naumova, R, 1986) |
| "Large Achilles tendon xanthomas of the type found in severe familial hypercholesterolemia were the first manifestation of cholestanolosis (cerebrotendinous xanthomatosis) in our patient, an otherwise asymptomatic normolipidemic 21-year-old woman." | 1.27 | Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia. ( Cantin, M; Davignon, J; Lussier-Cacan, S; Nestruck, AC; Roy, CC; Sniderman, AD, 1986) |
| "Clofibrate treatment resulted in a reduction of plasma cholesterol, hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities." | 1.26 | Effect of probucol on cholesterol metabolism in the rat. ( Holets, RJ; Kottke, BA; Li, JR, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (56.00) | 18.7374 |
| 1990's | 10 (40.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donatelli, L | 1 |
| Bobkova, VI | 1 |
| Lokshina, LI | 1 |
| Sidakova, MM | 1 |
| Tananova, GV | 1 |
| Fomchenkov, SI | 1 |
| Atmeh, RF | 1 |
| Stewart, JM | 1 |
| Boag, DE | 1 |
| Packard, CJ | 1 |
| Lorimer, AR | 1 |
| Shepherd, J | 1 |
| Saunders, RN | 1 |
| Azarnoff, DL | 1 |
| Li, JR | 1 |
| Holets, RJ | 1 |
| Kottke, BA | 1 |
| Scebat, L | 1 |
| Renais, J | 1 |
| Dujovne, CA | 1 |
| Harris, WS | 1 |
| Gerrond, LL | 1 |
| Fan, J | 1 |
| Muzio, F | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Tvorogova, MG | 1 |
| Lupanov, VP | 1 |
| Nuraliev, EIu | 1 |
| Zaĭtseva, TM | 2 |
| Kukharchuk, VV | 1 |
| Titov, VN | 2 |
| Toyota, Y | 1 |
| Yamamura, T | 1 |
| Miyake, Y | 1 |
| Yamamoto, A | 2 |
| Dalmau Serra, J | 1 |
| Hirano, T | 1 |
| Mamo, JC | 1 |
| Nagano, S | 1 |
| Sugisaki, T | 1 |
| Vogt, HB | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Szostak, WB | 1 |
| Murase, T | 1 |
| Hunninghake, DB | 1 |
| Saito, Y | 1 |
| Yoshida, S | 1 |
| Matsuzawa, Y | 1 |
| Yamashita, S | 1 |
| Funahashi, T | 1 |
| Tarui, S | 1 |
| Davignon, J | 2 |
| Blum, CB | 1 |
| Levy, RI | 2 |
| Naumova, R | 1 |
| Kerekovska, M | 1 |
| Goranov, I | 1 |
| Balabanski, L | 1 |
| Lussier-Cacan, S | 1 |
| Cantin, M | 1 |
| Roy, CC | 1 |
| Sniderman, AD | 1 |
| Nestruck, AC | 1 |
| Schaefer, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for probucol and Hyperlipoproteinemias
| Article | Year |
|---|---|
[Pharmacology of probucol. I].
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Cholesterol; Clofibra | 1984 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; H | 1982 |
[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Arterioscle | 2000 |
Hyperlipoproteinemias: part IV. Drug regimens.
Topics: Anticholesteremic Agents; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Niacin; Probucol | 1991 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
1 trial available for probucol and Hyperlipoproteinemias
| Article | Year |
|---|---|
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; H | 1982 |
18 other studies available for probucol and Hyperlipoproteinemias
| Article | Year |
|---|---|
[Evaluation of the effectiveness of hypolipidemic preparations in coronary arteriosclerosis].
Topics: Coronary Disease; Drug Evaluation; Glucose Tolerance Test; Humans; Hyperlipoproteinemias; Hypolipide | 1984 |
The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; | 1983 |
Effect of probucol on cholesterol metabolism in the rat.
Topics: Animals; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Hydroxymethylglutary | 1980 |
[Prolonged probucol treatment in patients with cardiovascular diseases (author's transl)].
Topics: Adult; Aged; Anticoagulants; Cardiovascular Diseases; Cholesterol; Diuretics; Drug Interactions; Fem | 1980 |
Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia.
Topics: Antioxidants; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemias; Lipoprotei | 1994 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
[A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia].
Topics: Adult; Aged; Apolipoproteins; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relatio | 1998 |
Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia.
Topics: Adult; Bezafibrate; Female; Humans; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agent | 1999 |
[Drug therapy of hyperlipoproteinemias].
Topics: Adolescent; Child; Child, Preschool; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglut | 1991 |
The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Hyperlipoproteinemias; Kidney; Male; Nephrotic Syndrome; Organ Size; Probu | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; | 1991 |
[Hyperlipoproteinemia: classification and current problems].
Topics: Diet; Heptanoic Acids; Humans; Hyperlipoproteinemias; Lipoproteins; Naphthalenes; Pravastatin; Probu | 1990 |
[Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Blood Component Removal; Cholesterol; Drug Therapy, Combinati | 1989 |
Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Corneal | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Human | 1986 |
[Clinical research on the hypolipidemic action of a probucol preparation].
Topics: Adult; Cholesterol; Drug Evaluation; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type | 1986 |
Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia.
Topics: Adult; Apolipoproteins B; Bile; Bile Acids and Salts; Cholesterol; Dietary Fats; Female; Humans; Hyp | 1986 |